S&R FARMACEUTICI IN UROLOGY, WHY THIS DECISION?

During the Company implementation step, it was decided to broaden the horizons of S&R Farmaceutici to embrace the specialisation of Urology, in light of two essential prerequisites:

• Urology remains an Area that is not crowded by too many Pharmaceutical Companies; the Urologist Specialist appears to be a doctor who is highly attentive to the prescription of medicines as well as MDs and supplements (SPM IMS Data).
  The Company has widespread national coverage and as such it up to the task of providing suitable coverage for the number of Urologists present in the country (4,000).
• S&R will be able to release innovative MDs and Supplements onto the market, developed thanks to its very own Internal Research division and will have immense potential in terms of the souring of Medicines for this Treatment Area compared to other specialisations.

The aim of the Company will be to bring turnover from this new Target to 1/3 of the Company’s Total, by focusing activities on Urologists, so that it is recognised by them as an Italian Company capable of brining innovation to this field.

The process of penetration into Urology will take place with the launch of three new widely used prescription Medicines, Fosfomycin Trometamol, Dutasteride and Serenoa Repens.

September 2017 marks the beginning of penetration by S&R Farmaceutici onto a market of significant interest, rich in opportunities for optimal Company development.